Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 14/20 | 0.72 |
| ▸ | PLAU | P00749 | 2/20 | 0.42 |
| ▸ | F11 | P03951 | 2/20 | 0.39 |
| ▸ | TPSB2 | P20231 | 2/20 | 0.39 |
| ▸ | PLG | P00747 | 1/20 | 0.39 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.39 |
| ▸ | F7 | P08709 | 1/20 | 0.39 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.32 |
| ▸ | SELL | P14151 | 1/20 | 0.32 |
| ▸ | SELP | P16109 | 1/20 | 0.32 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25879828 | 0.89 | CFD (0.58) | CFDPLAUHDAC1 | |
| SCHEMBL21439662 | 0.84 | CFD (1.00) | CFDF11TPSB2HDAC1SUCNR1 | |
| SCHEMBL25879832 | 0.83 | CFD (0.51) | CFD | |
| SCHEMBL25893039 | 0.76 | CFD (0.46) | CFDHDAC1 | |
| SCHEMBL21438524 | 0.75 | CFD (0.80) | CFDF11TPSB2HDAC1SUCNR1 | |
| SCHEMBL25879834 | 0.74 | CFD (0.55) | CFD | |
| SCHEMBL25879837 | 0.74 | CFD (0.51) | CFDPLAU | |
| SCHEMBL21438222 | 0.70 | CFD (0.80) | CFDPLAUF11TPSB2PLG | |
| SCHEMBL31266531 | 0.70 | CFD (0.80) | CFDPLAUF11TPSB2PLG | |
| SCHEMBL21439748 | 0.69 | CFD (0.75) | CFDF11TPSB2SUCNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2023-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11708347-B2 | Substituted benzofuran, benzopyrrole, benzothiophene, and structurally related complement inhibitors | C9, C5, C1QBP | CFD 17/4885PLAU 2021/4885F11 216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.